Haoxi Health Technology Closes Follow-On Offering
Ticker: HAO · Form: 6-K · Filed: Sep 23, 2024 · CIK: 1954594
| Field | Detail |
|---|---|
| Company | Haoxi Health Technology LTD (HAO) |
| Form Type | 6-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $3.00, $3, $12,000,000, b, $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: follow-on offering, capital raise, equity
TL;DR
Haoxi Health closed a 4M unit offering on 9/20/24, raising capital.
AI Summary
On September 20, 2024, Haoxi Health Technology Limited closed an underwritten follow-on offering of 4,000,000 units. The filing does not specify the price per unit or the total gross proceeds from this offering.
Why It Matters
This offering provides Haoxi Health Technology with additional capital, which could be used for expansion, debt reduction, or other strategic initiatives, potentially impacting its future growth and stock value.
Risk Assessment
Risk Level: medium — Follow-on offerings can dilute existing shareholders' ownership and may indicate the company needs capital, but the specific use of funds and market reception are key factors.
Key Numbers
- 4,000,000 — Units Offered (Represents the total number of units sold in the follow-on offering.)
Key Players & Entities
- Haoxi Health Technology Limited (company) — The company that closed the offering.
- September 20, 2024 (date) — The closing date of the offering.
- 4,000,000 units (dollar_amount) — The number of units offered and sold.
FAQ
What was the gross and net proceeds from the follow-on offering?
The filing states that 4,000,000 units were sold, but does not specify the price per unit or the total gross and net proceeds raised.
What is the intended use of the proceeds from this offering?
The filing does not detail the specific use of the proceeds from the follow-on offering.
Who were the underwriters for this follow-on offering?
The filing mentions an 'underwritten' offering but does not name the specific underwriters involved.
What does each 'Unit' consist of in this offering?
Each Unit consists of common stock and warrants, though the exact number of shares and warrants per unit is not fully detailed in the provided text.
What is the ticker symbol for Haoxi Health Technology Limited?
The filing does not explicitly state the ticker symbol, but the SEC file number is 001-41933.
Filing Stats: 1,189 words · 5 min read · ~4 pages · Grade level 13.3 · Accepted 2024-09-23 10:41:09
Key Financial Figures
- $0.0001 — ) one Class A Ordinary Share, par value $0.0001 per share (the “Class A Ordinary
- $3.00 — dquo;), at the public offering price of $3.00 per Unit. The Class A Ordinary Shares u
- $3 — Shares.” Each Unit was priced at $3.00, and the Company generated gross pro
- $12,000,000, b — the Company generated gross proceeds of $12,000,000, before deducting offering expenses. The
- $0 — he Series A Warrant will be adjusted to $0.60, i.e., one fifth of the per Unit off
Filing Documents
- ea0215292-6k_haoxi.htm (6-K) — 29KB
- ea021529201ex5-2_haoxi.htm (EX-5.2) — 16KB
- ea021529201ex99-1_haoxi.htm (EX-99.1) — 284KB
- ea021529201ex99-2_haoxi.htm (EX-99.2) — 105KB
- ea021529201ex99-3_haoxi.htm (EX-99.3) — 143KB
- ea021529201ex99-4_haoxi.htm (EX-99.4) — 145KB
- ea021529201ex99-5_haoxi.htm (EX-99.5) — 98KB
- ea021529201ex99-6_haoxi.htm (EX-99.6) — 12KB
- ea021529201ex99-7_haoxi.htm (EX-99.7) — 11KB
- ex5-2_001.jpg (GRAPHIC) — 13KB
- 0001213900-24-080878.txt ( ) — 862KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Haoxi Health Technology Limited Date: September 23, 2024 By: /s/ Zhen Fan Name: Zhen Fan Title: Chief Executive Officer 2 EXHIBIT INDEX Exhibit No. Description 5.2 Opinion of Hunter Taubman Fischer & Li LLC, U.S. counsel to Company, as to the enforceability of the Warrants 99.1 The Underwriting Agreement 99.2 Form of Pre-funded Warrant 99.3 Form of Series A Warrant 99.4 Form of Series B Warrant 99.5 The Warrant Agent Agreement 99.6 Pricing Press Release 99.7 Closing Press Release 3